The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Recombinant Urate Oxidase for the Prophylaxis or Treatment of Hyperuricemia in Patients With Leukemia or Lymphoma
Abstract
PURPOSE: To improve the control of hyperuricemia in patients with leukemia or lymphoma, we tested a newly developed uricolytic agent, recombinant urate oxidase (SR29142; Rasburicase; Sanofi-Synthelabo, Inc, Paris, France), which catalyzes the oxidation of uric acid to allantoin, a highly water-soluble metabolite readily excreted by the kidneys. PATIENTS AND METHODS: We administered Rasburicase intravenously, at 0.15 or 0.20 mg/kg, for 5 to 7 consecutive days to 131 children, adolescents, and young adults with newly diagnosed leukemia or lymphoma, who either presented with abnormally high plasma uric acid concentrations or had large tumor cell burdens. Blood levels of uric acid, creatinine, phosphorus, and potassium were measured daily. The pharmacokinetics of Rasburicase, the urinary excretion rate of allantoin, and antibodies to Rasburicase were also studied. RESULTS: At either dosage, the recombinant enzyme produced a rapid and sharp decrease in plasma uric acid concentrations in all patients. The median level decreased by 4 hours after treatment, from 9.7 to 1 mg/dL (P = .0001), in the 65 patients who presented with hyperuricemia, and from 4.3 to 0.5 mg/dL (P = .0001) in the remaining 66 patients. Despite cytoreductive chemotherapy, plasma uric acid concentrations remained low throughout the treatment (daily median level, 0.5 mg/dL). The urinary excretion rate of allantoin increased during Rasburicase treatment, peaking on day 3. Serum phosphorus concentrations did not change significantly during the first 3 days of treatment, decreased significantly by day 4 in patients presenting with hyperuricemia (P = .0003), and fell within the normal range in all patients by 48 hours after treatment. Serum creatinine levels decreased significantly after 1 day of treatment in patients with or without hyperuricemia at diagnosis (P = .0003 and P = .02, respectively) and returned to normal range in all patients by day 6 of treatment. Toxicity was negligible, and none of the patients required dialysis. The mean plasma half-lives of the agent were 16.0 ± 6.3 (SD) hours and 21.1 ± 12.0 hours, respectively, in patients treated at dosages of 0.15 or 0.20 mg/kg. Seventeen of the 121 assessable patients developed antibodies to the enzyme. CONCLUSION: Rasburicase is safe and highly effective for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pui, C.-H., & Evans, W. E. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808273390907 · Cited by 832
Self-citationCohen, L. F., Balow, J. E., MAGRATH, I. T., Poplack, D. G., & Ziegler, J. L. (1980) · The American Journal of Medicine · doi:10.1016/0002-9343(80)90286-7 · Cited by 431
The Effectiveness of the Xanthine Oxidase Inhibitor Allopurinol in the Treatment of Gout
KLINENBERG, J. R., GOLDFINGER, S. E., & SEEGMILLER, J. E. (1965) · Annals of Internal Medicine · doi:10.7326/0003-4819-62-4-639 · Cited by 214
Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies
Pui, C.-H., Relling, M., Lascombes, F., Harrison, P., Struxiano, A., Mondesir, J.-M., Ribeiro, R., Sandlund, J., Rivera, G., Evans, W., et al. (1997) · Leukemia · doi:10.1038/sj.leu.2400850 · Cited by 174
Self-citationBowman, W. P., Shuster, J. J., Cook, B., Griffin, T., Behm, F., Pullen, J., Link, M., Head, D., Carroll, A., Berard, C., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.4.1252 · Cited by 166
Urinary Xanthine Stones-a Rare Complication of Allopurinol Therapy
Greene, M. L., Fujimoto, W. Y., & Seegmiller, J. E. (1969) · New England Journal of Medicine · doi:10.1056/nejm196902202800806 · Cited by 165
Uric acid excretion and renal function in the acute hyperuricemia of leukemia
Rieselbach, R. E., Bentzel, C. J., Cotlove, E., Frei, E., & Freireich, E. J. (1964) · The American Journal of Medicine · doi:10.1016/0002-9343(64)90130-5 · Cited by 136
Molecular evolution of the urate oxidase-encoding gene in hominoid primates: nonsense mutations
Yeldandi, A. V., Yeldandi, V. V., Kumar, S., Murthy, C. V. N., Wang, X., Alvares, K., Rao, M. S., & Reddy, J. K. (1991) · Gene · doi:10.1016/0378-1119(91)90622-i · Cited by 104
Ablin, A. R., Stephens, B. G., Hirata, T., Wilson, K. M., & Williams, H. E. (1972) · Metabolism · doi:10.1016/0026-0495(72)90124-2 · Cited by 53
Berthemy, A., Newton, J. F., Wu, D., & Buhrman, D. (1999) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/s0731-7085(98)00200-3 · Cited by 37
Cited by
Howard, S. C., Jones, D. P., & Pui, C.-H. (2011) · New England Journal of Medicine · doi:10.1056/nejmra0904569 · Cited by 1,044
Self-citationDrug-induced acute kidney injury
Schetz, M., Dasta, J., Goldstein, S., & Golper, T. (2005) · Current Opinion in Critical Care · doi:10.1097/01.ccx.0000184300.68383.95 · Cited by 313
Metadata
- Authors
- Pui, C.-H., Mahmoud, H. H., Wiley, J. M., Woods, G. M., Leverger, G., Camitta, B., Hastings, C., Blaney, S. M., Relling, M. V., & Reaman, G. H.
- Venue
- Journal of Clinical Oncology
- Published
- 2001-02-01
- Volume
- 19
- Issue
- 3
- Pages
- 697-704
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2155080284
- Cited by
- 361
- References
- 10
- FWCI
- 13.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recombinant Urate Oxidase for the Prophylaxis or Treatment of Hyperuricemia in Patients With Leukemia or Lymphoma. https://app.cochat.ai/papers/10.1200/jco.2001.19.3.697
- The paper
- Pui, C.-H., Mahmoud, H. H., Wiley, J. M., Woods, G. M., Leverger, G., Camitta, B., Hastings, C., Blaney, S. M., Relling, M. V., & Reaman, G. H. (2001). Recombinant Urate Oxidase for the Prophylaxis or Treatment of Hyperuricemia in Patients With Leukemia or Lymphoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2001.19.3.697
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
